| 1. |
Another look at MAO-B inhibitors in early Parkinson's disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1455,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Major medical journals adopt new trials registration policy |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1455,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Galantamine worth it for AD in many countries |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1455,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
ACE inhibitors"widely underprescribed"in the US |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1455,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
R&D news from the 9th International Conference on Alzheimer's Disease |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1455,
2004,
Page 6-7
S. Sullivan,,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Modified-release indiplon*is effective for the treatment of elderly patients with chronic insomnia, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1455,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Fluvastatin [Lescol] therapy reduces cardiac events without compromising renal function in renal transplant recipients with mild-to-moderate hypercholesterolaemia, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1455,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Lopinavir/ritonavir single agent therapy feasible for HIV infections? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1455,
2004,
Page 9-10
&NA;,
Preview
|
|
摘要:
Single agent therapy for the treatment of HIV infection has a number of advantages over combination therapy. Firstly, exposure to fewer antiretroviral agents may reduce the risk of adverse events and secondly, future treatment options are preserved. Furthermore, having fewer tablets to take may improve compliance and is likely to be less expensive than multidrug regimes. Lopinavir/ritonavir [Kaletra] has ideal characteristics for single agent therapy, with high potency and an apparent lack of genotypic or phenotypic resistance, and studies presented at the XV International AIDS Conference [Bangkok, Thailand; July 2004] have shown single agent therapy with lopinavir/ritonavir to be feasible, although this needs to be confirmed in large clinical trials.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Treatment with topical tazarotene results in partial or complete regression of most neoplasms in patients with basal cell cancer (BCC), |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1455,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Tirofiban (high-dose bolus) effective in PCI |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1455,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
